Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OmegaD in Dry Eye Disease
NCT02980224Phase 3Completed
- Sponsor
- OmegaD
- Start
- Oct 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye disease (DED) comparing OmegaD with Placebo (2 arms). Primary endpoints: Tear Break up Time at 84 Days and Ocular Surface Disease Index at 84 Days. Started Oct 2016; status: completed.
02
Drugs
OmegaD
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT02980224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980224.